Literature DB >> 33593948

Diagnosis and treatment of adenomyosis.

Ebernella Shirin Dason1, Crystal Chan2, Mara Sobel2.   

Abstract

Entities:  

Year:  2021        PMID: 33593948      PMCID: PMC8034338          DOI: 10.1503/cmaj.201607

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.

Adenomyosis is a common cause of dysmenorrhea and heavy menstrual bleeding

Adenomyosis is a benign gynecological disorder characterized by aberrant development of endometrial glands and stroma within the myometrium, causing inflammation and neuroangiogenesis.1,2 Adenomyosis often coexists with other gynecological conditions and may cloud the clinical presentation (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.201607/tab-related-content).1

Adenomyosis can affect any reproductive-aged woman, with incidence and severity increasing with age

Historically thought to affect only older women, adenomyosis is now identifiable on imaging in 30% of women younger than 40 years.1,2 Up to 30% of women with adenomyosis are asymptomatic and symptoms resolve after menopause; asymptomatic or menopausal women do not require management.1,3,4

Transvaginal ultrasound is the first-line diagnostic test for adenomyosis

All women presenting with dysmenorrhea or heavy menstrual bleeding should receive a transvaginal ultrasound to assess for adenomyosis as well as to exclude other structural causes (e.g., polyps, fibroids). Transvaginal ultrasound has a sensitivity of 83.8% and specificity of 63.9% for adenomyosis, and confirmatory testing with magnetic resonance imaging is usually not required.2

Medical management is effective for symptom control in most women with adenomyosis

Empiric therapy may be started before ultrasound results are received. The levonorgestrel intrauterine system is the most-studied treatment, with the largest randomized controlled trial (n = 86) showing comparable improvement in hemoglobin and quality of life compared with hysterectomy at 6 months.5 Other treatments include tranexamic acid, nonsteroidal anti-inflammatory drugs, combined hormonal contraceptives and other progestins (norethindrone acetate, medroxyprogesterone, dienogest). If initial treatment fails after 3–6 months, referral to a gynecologist is suggested, to consider other medical (i.e., gonadotropin-releasing hormone agonists), interventional or surgical options.1,3,5

Adenomyosis, whether symptomatic or asymptomatic, may affect fertility

Referral to a fertility specialist is appropriate for patients presenting with subfertility or recurrent miscarriage, especially after the age of 35 years.

CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj
  5 in total

Review 1.  Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis.

Authors:  Stephan Gordts; Grigoris Grimbizis; Rudi Campo
Journal:  Fertil Steril       Date:  2018-03       Impact factor: 7.329

Review 2.  Role of medical therapy in the management of uterine adenomyosis.

Authors:  Silvia Vannuccini; Stefano Luisi; Claudia Tosti; Flavia Sorbi; Felice Petraglia
Journal:  Fertil Steril       Date:  2018-03       Impact factor: 7.329

3.  Diagnosing adenomyosis: an integrated clinical and imaging approach.

Authors:  Charles Chapron; Silvia Vannuccini; Pietro Santulli; Mauricio S Abrão; Francisco Carmona; Ian S Fraser; Stephan Gordts; Sun-Wei Guo; Pierre-Alexandre Just; Jean-Christophe Noël; George Pistofidis; Thierry Van den Bosch; Felice Petraglia
Journal:  Hum Reprod Update       Date:  2020-02-25       Impact factor: 15.610

4.  Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015.

Authors:  Onchee Yu; Renate Schulze-Rath; Jane Grafton; Kelly Hansen; Delia Scholes; Susan D Reed
Journal:  Am J Obstet Gynecol       Date:  2020-01-15       Impact factor: 8.661

5.  Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review.

Authors:  Cristina Laguna Benetti-Pinto; Ticiana Aparecida Alves de Mira; Daniela Angerame Yela; Cassia Raquel Teatin-Juliato; Luiz Gustavo Oliveira Brito
Journal:  Rev Bras Ginecol Obstet       Date:  2019-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.